Nanoengineering of vaccines using natural polysaccharides

Biotechnology Advances

Volumn 33, Issue 6, 2015, Pages 1279-1293

  Cordeiro, Ana Sara ^a,b   Alonso, María José ^a   de la Fuente, María ^b  

^a Universidade de Santiago de Compostela and Instituto de Investigación Sanitaria de Santiago de Compostela   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Adjuvants; Antigen delivery; Antigens; Nanovaccine; Needle free vaccination; Polysaccharides

Indexed keywords

ANTIGENS; BIOCOMPATIBILITY; BIODEGRADATION; NEEDLES; NUCLEIC ACIDS; POLYSACCHARIDES; PROTEINS; VACCINES; VIRUSES;

ADJUVANTS; ANTIGEN DELIVERY; BIOTECHNOLOGICAL ADVANCES; DEVELOPMENT AND APPLICATIONS; NANOVACCINE; NATURAL INFECTION; NATURAL POLYSACCHARIDE; SPECIFIC LOCATION;

IMMUNE SYSTEM;

ANTIGEN; BACTERIUM; BIOENGINEERING; DRUG DEVELOPMENT; IMMUNE RESPONSE; NANOPARTICLE; NANOTECHNOLOGY; PATHOGEN; POLYSACCHARIDE; VACCINATION; VACCINE; VIRUS;

ANTIGEN; BETA GLUCAN; CHITOSAN; DEXTRAN; DNA VACCINE; IMMUNOLOGICAL ADJUVANT; MANNAN; POLYSACCHARIDE; RECOMBINANT PROTEIN; VACCINE;

CHEMISTRY; GENETICS; HUMAN; IMMUNOLOGY; NANOTECHNOLOGY; PROCEDURES;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS; BETA-GLUCANS; CHITOSAN; DEXTRANS; HUMANS; MANNANS; NANOTECHNOLOGY; POLYSACCHARIDES; RECOMBINANT PROTEINS; VACCINES; VACCINES, DNA;

EID: 84955193152     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2015.05.010     Document Type: Review

References (179)

1. Adams E.L., Rice P.J., Graves B., Ensley H.E., Yu H., Brown G.D., et al. Differential high-affinity interaction of Dectin-1 with natural or synthetic glucans is dependent upon primary structure and is influenced by polymer chain length and side-chain branching. J. Pharmacol. Exp. Ther. 2008, 325(1):115-123.
2. Aguilar J., Rodríguez E. Vaccine adjuvants revisited. Vaccine 2007, 25(19):3752-3762.
3. Ai W., Yue Y., Xiong S., Xu W. Enhanced protection against pulmonary mycobacterial challenge by chitosan-formulated polyepitope gene vaccine is associated with increased pulmonary secretory IgA and gamma-interferon+T cell responses. Microbiol. Immunol. 2013, 57:224-235.
4. Aide P., Dobaño C., Sacarlal J., Aponte J.J., Mandomando I., Guinovart C., et al. Four year immunogenicity of the RTS, S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial. Vaccine 2011, 29(35):6059-6067.
5. Al-Barwani F., Young S.L., Baird M.A., Larsen D.S., Ward V.K. Mannosylation of virus-like particles enhances internalization by antigen presenting cells. PLoS One 2014, 9(8):e104523. (Jan).
6. Alonso M.J., Gupta R.K., Min C., Siber G.R., Langer R.S. Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. Vaccine 1994, 12(4):299-306.
7. Alonso-Sande M., Cuña M., Remuñán-López C., Teijeiro-Osorio D., Alonso-Lebrero J.L., Alonso M.J. Formation of new glucomannan-chitosan nanoparticles and study of their ability to associate and deliver proteins. Macromolecules 2006, 39(12):4152-4158. (American Chemical Society).
8. Alonso-Sande M., Teijeiro-Osorio D., Remuñán-López C., Alonso M.J. Glucomannan, a promising polysaccharide for biopharmaceutical purposes. Eur. J. Pharm. Biopharm. 2009, 72(2):453-462. (Jun).
9. Alpar H.O., Papanicolaou I., Bramwell V.W. Strategies for DNA vaccine delivery. Expert Opin. Drug Deliv. 2005, 2(5):829-842.
10. Amorij J.P., Kersten G.F., Saluja V., Tonnis W.F., Hinrichs W.L., Slütter B., et al. Towards tailored vaccine delivery: needs, challenges and perspectives. J. Control. Release 2012, 161(2):363-367. (Elsevier B.V.).
11. Apostolopoulos V., Thalhammer T., Tzakos A.G., Stojanovska L. Targeting antigens to dendritic cell receptors for vaccine development. J. Drug Deliv. 2013, 2013(ii):869718. (Jan).
12. Arca H.C., Günbeyaz M., Senel S. Chitosan-based systems for the delivery of vaccine antigens. Expert Rev. Vaccines 2009, 8(7):937-953. (Jul).
13. Atmar R.L., Bernstein D.I., Harro C.D., Al-Ibrahim M.S., Chen W.H., Ferreira J., et al. Norovirus vaccine against experimental human Norwalk virus illness. N. Engl. J. Med. 2011, 365(23):2178-2187.
14. Azmi F., Fuaad A.A.H.A., Skwarczynski M., Toth I. Recent progress in adjuvant discovery for peptide-based subunit vaccines. Hum. Vaccin. Immunother. 2014, 10(3).
15. Bachmann M.F., Jennings G.T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 2010, 10(11):787-796. (Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved).
16. Bal S.M., Slütter B., Verheul R., Bouwstra J.A., Jiskoot W. Adjuvanted, antigen loaded N-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: adjuvant- and site-dependent immunogenicity in mice. Eur. J. Pharm. Sci. 2012, 45(4):475-481. (Elsevier B.V.).
17. Baldwin A.D., Kiick K.L. Polysaccharide-modified synthetic polymeric biomaterials. Biopolymers 2010, 94(1):128-140. (Jan).
18. Barr I., Sjölander A., Cox J.C. ISCOMs and other saponin based adjuvants. Adv. Drug Deliv. Rev. 1998, 32(3):247-271.
19. Barsanti L., Passarelli V., Evangelista V., Frassanito A.M., Gualtieri P. Chemistry, physico-chemistry and applications linked to biological activities of [small beta]-glucans. Nat. Prod. Rep. 2011, 28(3):457-466. (The Royal Society of Chemistry, Mar).
20. BatzloffM.R., Sriprakash K., Good M.F. Vaccine development for group A streptococcus infections and associated diseases. Curr. Drug Targets 2004, 5(1):57-69.
21. Behrens R.H., Cramer J.P., Jelinek T., Shaw H., von Sonnenburg F., Wilbraham D., et al. Efficacy and safety of a patch vaccine containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala. Lancet Infect. Dis. 2014, 14(13):197-204. (Elsevier Ltd.).
22. Blanco M., Alonso M.J. Development and characterization of protein-loaded poly(lactide-co-glycolide) nanospheres. Eur. J. Pharm. Biopharm. 1997, 43(3):287-294.
23. Boateng J.S., Matthews K.H., Stevens H.N., Eccleston G.M. Wound healing dressings and drug delivery systems: a review. J. Pharm. Sci. 2008, 97:2892-2923.
24. Bomford R. Aluminium salts: perspectives in their use as adjuvants. Immunol Adjuv Vaccines 1989, 35-42. Springer US, Boston, MA. G. Gregoriadis, A.C. Allison, G. Poste (Eds.).
25. Borges O.M., Silva M., de Sousa A., Borchard G., Junginger H.E., Cordeiro-da-Silva A. Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen. Int. Immunopharmacol. 2008, 8(13-14):1773-1780. (Elsevier B.V.; Dec 20).
26. Bose N., Chan A., Guerrero F., Maristany C., Qiu X., Walsh R., et al. Binding of soluble yeast β-glucan to human neutrophils and monocytes is complement-dependent. Front. Immunol. 2013, 4:230.
27. Calvo P., Remuñan-López C., Vila-Jato J.L., Alonso M.J. Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm. Res. 1997, 14(10):1431-1436. (Springer Netherlands).
28. Calvo P., Remuñán-López C., Vila-Jato J.L., Alonso M.J. Development of positively charged colloidal drug carriers: chitosan-coated polyester nanocapsules and submicron-emulsions. Colloid Polym. Sci. 1997, 275:46-53.
29. Calvo P., Remuñán-López C., Vila-Jato J.L., Alonso M.J. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J. Appl. Polym. Sci. 1997, 63(1):125-132.
30. Cambridge C.D., Singh S.R., Waffo A.B., Fairley S.J., Dennis V.A. Formulation, characterization, and expression of a recombinant MOMP Chlamydia trachomatis DNA vaccine encapsulated in chitosan nanoparticles. Int. J. Nanomedicine 2013, 8:1759-1771.
31. Chadwick S., Kriegel C., Amiji M. Nanotechnology solutions for mucosal immunization. Adv. Drug Deliv. Rev. 2010, 62(4-5):394-407.
32. Chen D., Zehrung D. Desirable attributes of vaccines for deployment in low-resource settings. J. Pharm. Sci. 2013, 102:29-33.
33. Chen L., Zhu J., Li Y., Lu J., Gao L., Xu H., et al. Enhanced nasal mucosal delivery and immunogenicity of anti-caries DNA vaccine through incorporation of anionic liposomes in chitosan/DNA complexes. PLoS One 2013, 8(8).
34. Correia-Pinto J., Csaba N., Alonso M.J. Vaccine delivery carriers: insights and future perspectives. Int. J. Pharm. 2013, 440(1):27-38.
35. Cox J.C., Coulter A.R. Adjuvants-a classification and review of their modes of action. Vaccine 1997, 15(3):248-256.
36. Csaba N., García-Fuentes M., Alonso M.J. Nanoparticles for nasal vaccination. Adv. Drug Deliv. Rev. 2009, 61(2):140-157.
37. Danhier F., Ansorena E., Silva J.M., Coco R., Le Breton A., Préat V. PLGA-based nanoparticles: an overview of biomedical applications. J. Control. Release 2012, 161(2):505-522.
38. de Belder A.N. Medical applications of dextran and its derivatives. Polysaccharides Med Appl 1996, 505-524. CRC Press, New York, USA. S. Dumitriu (Ed.).
39. De Temmerman M.-L., Rejman J., Demeester J., Irvine D.J., Gander B., De Smedt S.C. Particulate vaccines: on the quest for optimal delivery and immune response. Drug Discov. Today 2011, 16(13-14):569-582. (Elsevier Ltd; Jul).
40. Deering R.P., Kommareddy S., Ulmer J.B., Brito L.A., Geall A.J. Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines. Expert Opin. Drug Deliv. 2014, 11(6):885-899.
41. Delany I., Rappuoli R., De Gregorio E. Vaccines for the 21st century. EMBO Mol. Med. 2014, 6(6):708-720.
42. Demento S.L., Siefert A.L., Bandyopadhyay A., Sharp F.A., Fahmy T.M. Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines. Trends Biotechnol. 2011, 29(6):294-306.
43. Des Rieux A., Fiévez V., Garinot M., Schneider Y.-J.J., Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Release 2006, 116(1):1-27. (Nov).
44. Desai M., Labhasetwar V., Amidon G., Levy R. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res. 1996, 13(12):1838-1845.
45. Donati C., Rappuoli R. Reverse vaccinology in the 21st century: improvements over the original design. Ann. N. Y. Acad. Sci. 2013, 1285:115-132.
46. Drogoz A., Munier S., Verrier B., David L., Domard A., Delair T. Towards biocompatible vaccine delivery systems: interactions of colloidal PECs based on polysaccharides with HIV-1 p24 antigen. Biomacromolecules 2008, 9(2):583-591. (Feb).
47. Dube A., Reynolds J.L., Law W.-C., Maponga C.C., Prasad P.N., Morse G.D. Multimodal nanoparticles that provide immunomodulation and intracellular drug delivery for infectious diseases. Nanomed. Nanotechnol. Biol. Med. 2014, 10(4):831-838.
48. Duncan R., Gaspar R. Nanomedicine(s) under the microscope. Mol. Pharm. 2011, 8(6):2101-2141.
49. Durán-Lobato M., Carrillo-Conde B.R., Khairandish Y., Peppas N.A. Surface-modified P (HEMA-co-MAA) nanogel carriers for oral vaccine delivery: design, characterization, and in vitro targeting evaluation. Biomacromolecules 2014, 15(7):2725-2734. (Jul 14).
50. Dykstra T., Utermoehlen O., Haas A. Defined particle ligands trigger specific defense mechanisms of macrophages. Innate Immun. 2011, 17(4):388-402. (Aug).
51. Esposito S., Tagliaferri L., Daleno C., Valzano A., Picciolli I., Tel F., et al. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents. Vaccine 2011, 29(8):1677-1682.
52. Etheridge M.L., Campbell S.A., Erdman A.G., Haynes C.L., Wolf S.M., McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomed. Nanotechnol. Biol. Med. 2013, 9(1):1-14.
53. Feng G., Jiang Q., Xia M., Lu Y., Qiu W., Zhao D., et al. Enhanced immune response and protective effects of nano-chitosan-based DNA vaccine encoding T cell epitopes of Esat-6 and FL against Mycobacterium tuberculosis infection. PLoS One 2013, 8(4).
54. Fifis T., Gamvrellis A., Crimeen-Irwin B., Pietersz G.A., Li J., Mottram P.L., et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J. Immunol. 2004, 173(5):3148-3154. (Aug 20).
55. Figueiredo L., Cadete A., Gonçalves L., Corvo M., Almeida A.J. Intranasal immunisation of mice against Streptococcus equi using positively charged nanoparticulate carrier systems. Vaccine 2012, 30(46):6551-6558. (Oct 12).
56. Finnerty M., Enright W., Morrison C., Roche J. Immunization of bull calves with a GnRH analogue-human serum albumin conjugate: effect of conjugate dose, type of adjuvant and booster interval on immune, endocrine, testicular and growth responses. J. Reprod. Fertil. 1994, 101:333-343.
57. Fox C.B. Squalene emulsions for parenteral vaccine and drug delivery. Molecules 2009, 14(9):3286-3312.
58. Fox C.B., Kramer R.M., Barnes V.L., Dowling Q.M., Vedvick T.S. Working together: interactions between vaccine antigens and adjuvants. Ther. Adv. Vaccines 2013, 1(1):7-20.
59. Frech S.A., Dupont H.L., Bourgeois A.L., McKenzie R., Belkind-Gerson J., Figueroa J.F., et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet 2008, 371(9629):2019-2025. (Jun 14).
60. García-Fuentes M., Alonso M.J. Chitosan-based drug nanocarriers: where do we stand?. J. Control. Release 2012, 161(2):496-504.
61. Ghotbi Z., Haddadi A., Hamdy S., Hung R.W., Samuel J., Lavasanifar A. Active targeting of dendritic cells with mannan-decorated PLGA nanoparticles. J. Drug Target. 2011, 19(4):281-292. (May).
62. Girard M.P., Osmanov S.K., Kieny M.P. A review of vaccine research and development: the human immunodeficiency virus (HIV). Vaccine 2006, 24(19):4062-4081. (May 8).
63. Giudice E.L., Campbell J.D. Needle-free vaccine delivery. Adv. Drug Deliv. Rev. 2006, 58(1):68-89.
64. Glenn G.M., Thomas D.N., Poffenberger K.L., Flyer D.C., Ellingsworth L.R., Andersen B.H., et al. Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch. Vaccine 2009, 27S(Suppl. 6):G60-G66. (Dec 30).
65. Gomes C.P., Ferreira Lopes C.D., Duarte Moreno P.M., Varela-Moreira A., Alonso M.J., Pêgo A.P., et al. Translating chitosan to clinical delivery of nucleic acid-based drugs. MRS Bull. 2014, 39(01):60-70. (Jan 10).
66. González-Aramundiz J.V., Cordeiro A.S., Csaba N., de la Fuente M., Alonso M.J. Nanovaccines: nanocarriers for antigen delivery. Biol. Aujourdhui 2012, 206(4):249-261.
67. Goodridge H.S., Wolf A.J., Underhill D.M. β-Glucan recognition by the innate immune system. Immunol. Rev. 2009, 230(1):38-50. (Blackwell Publishing Ltd).
68. Gori A., Longhi R., Peri C., Colombo G. Peptides for immunological purposes: design, strategies and applications. Amino Acids 2013, 45(2):257268.
69. Gou M., Dai M., Li X., Yang L., Huang M., Wang Y., et al. Preparation of mannan modified anionic PCL-PEG-PCL nanoparticles at one-step for bFGF antigen delivery to improve humoral immunity. Colloids Surf. B: Biointerfaces 2008, 64(1):135-139. (Jun 15).
70. Grabovac V., Guggi D., Bernkop-Schnürch A. Comparison of the mucoadhesive properties of various polymers. Adv. Drug Deliv. Rev. 2005, 57(11):1713-1723. (Nov 3).
71. Gutierro I., Hernández R.M., Igartua M., Gascón A.R., Pedraz J.L. Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine 2002, 21(1-2):67-77.
72. Hamdy S., Haddadi A., Shayeganpour A., Samuel J. Activation of antigen-specific T cell-responses by mannan-decorated PLGA nanoparticles. Pharm. Res. 2011, 28(9):2288-2301.
73. Harde H., Agrawal A.K., Jain S. Development of stabilized glucomannosylated chitosan nanoparticles using tandem crosslinking method for oral vaccine delivery. Nanomedicine 2014, 9(16):2511-2529.
74. Hedlund J., Langer B., Konradsen H.B., Örtqvist Å. Negligible adjuvant effect for antibody responses and frequent adverse events associated with IL-12 treatment in humans vaccinated with pneumococcal polysaccharide. Vaccine 2002, 20:164-169.
75. Heuking S., Borchard G. Toll-like receptor-7 agonist decoration enhances the adjuvanticity of chitosan-DNA nanoparticles. J. Pharm. Sci. 2012, 101(3):1166-1177. (Mar).
76. Heuking S., Adam-Malpel S., Sublet E., Iannitelli A., Di Stefano A., Borchard G. Stimulation of human macrophages (THP-1) using Toll-like receptor-2 (TLR-2) agonist decorated nanocarriers. J. Drug Target. 2009, 17(8):662-670. (Sep).
77. Hill D.R., Ford L., Lalloo D.G. Oral cholera vaccines: use in clinical practice. Lancet Infect. Dis. 2006, 6:361-373.
78. Hughes H.P. Cytokine adjuvants: lessons from the past - guidelines for the future?. Vet. Immunol. Immunopathol. 1998, 63:131-138.
79. Huo Z., Sinha R., McNeela E.A., Borrow R., Giemza R., Cosgrove C., et al. Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed with chitosan. Infect. Immun. 2005, 73(12):8256-8265.
80. Islam M.A., Firdous J., Choi Y.-J., Yun C.-H., Cho C.-S. Design and application of chitosan microspheres as oral and nasal vaccine carriers: an updated review. Int. J. Nanomedicine 2012, 7:6077-6093. (Jan).
81. Jain S., Harde H., Indulkar A., Agrawal A.K. Improved stability and immunological potential of tetanus toxoid containing surface engineered bilosomes following oral administration. Nanomedicine 2014, 10(2):431-440.
82. Jain S., Indulkar A., Harde H., Agrawal A.K. Oral mucosal immunization using glucomannosylated bilosomes. J. Biomed. Nanotechnol. 2014, 10(6):932947.
83. Jani P.U., Halbert G.W., Langridge J., Florence A.T. Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J. Pharm. Pharmacol. 1990, 42(12):821-826. (Dec).
84. Joshi M.D., Unger W.J., Storm G., van Kooyk Y., Mastrobattista E. Targeting tumor antigens to dendritic cells using particulate carriers. J. Control. Release 2012, 161(1):25-37.
85. Joshi V.B., Geary S.M., Salem A.K. Biodegradable particles as vaccine delivery systems: size matters. AAPS J. 2013, 15(1):85-94.
86. Kanchan V., Panda A.K. Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response. Biomaterials 2007, 28(35):53445357.
87. Kean T., Roth S., Thanou M. Trimethylated chitosans as non-viral gene delivery vectors: cytotoxicity and transfection efficiency. J. Control. Release 2005, 103(3):643-653. (Apr 18).
88. Kerlin R., Watson D. Effect of dextran sulphate on IgG subclass of antibody in efferent popliteal lymph of sheep. Immunol. Cell Biol. 1987, 65(Pt 5):411-417. (Oct).
89. Kester K.E., Gray Heppner D., Moris P., Ofori-Anyinam O., Krzych U., Tornieporth N., et al. Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS, S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults. Vaccine 2014, 32:6683-6691. (Jun 18).
90. Khatri K., Goyal A.K., Gupta P.N., Mishra N., Mehta A., Vyas S.P. Surface modified liposomes for nasal delivery of DNA vaccine. Vaccine 2008, 26(18):2225-2233. (Apr 24).
91. Khatri K., Goyal A.K., Gupta P.N., Mishra N., Vyas S.P. Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B. Int. J. Pharm. 2008, 354:235-241.
92. Kramps T., Probst J. Messenger RNA-based vaccines: progress, challenges, applications. Wiley Interdiscip. Rev. RNA 2013, 4:737-749.
93. Kreuter J., Speiser P.P. New adjuvants on a polymethylmethacrylate base. Infect. Immun. 1976, 13(1):204-210.
94. Laroui H., Ingersoll S.A., Liu H.C., Baker M.T., Ayyadurai S., Charania M.A., et al. Dextran sodium sulfate (DSS) induces colitis in mice by forming nano-lipocomplexes with medium-chain-length fatty acids in the colon. PLoS One 2012, 7(3).
95. Leroux-Roels I., Koutsoukos M., Clement F., Steyaert S., Janssens M., Bourguignon P., et al. Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems. Vaccine 2010, 28(43):7016-7024.
96. Li G.P., Liu Z.G., Liao B., Zhong N.S. Induction of Th1-type immune response by chitosan nanoparticles containing plasmid DNA encoding house dust mite allergen Der p 2 for oral vaccination in mice. Cell. Mol. Immunol. 2009, 6(1):45-50.
97. Lindblad E.B. Aluminium adjuvants-in retrospect and prospect. Vaccine 2004, 22(27-28):3658-3668.
98. Lipinski T., Fitieh A., St Pierre J., Ostergaard H.L., Bundle D.R., Touret N. Enhanced immunogenicity of a tricomponent mannan tetanus toxoid conjugate vaccine targeted to dendritic cells via Dectin-1 by incorporating β-glucan. J. Immunol. 2013, 190(8):4116-4128. (Apr 15).
99. Liu M. DNA vaccines: a review. J. Intern. Med. 2003, 253(4):402410.
100. Lu Y., Kawakami S., Yamashita F., Hashida M. Development of an antigen-presenting cell-targeted DNA vaccine against melanoma by mannosylated liposomes. Biomaterials 2007, 28(21):3255-3262. (Jul).
101. Lugade A.A., Bharali D.J., Pradhan V., Elkin G., Mousa S.A., Thanavala Y. Single low-dose un-adjuvanted HBsAg nanoparticle vaccine elicits robust, durable immunity. Nanomedicine 2013, 9(7):923-934.
102. Lynch J.M., Briles D.E., Metzger D.W. Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect. Immun. 2003, 71(8):4780-4788.
103. Mallapragada S.K., Narasimhan B. Immunomodulatory biomaterials. Int. J. Pharm. 2008, 364(2):265-271.
104. Mazid R., Tan M.X., Danquah M.K. Molecular delivery of plasmids for genetic vaccination. Curr. Pharm. Biotechnol. 2013, 14(6):615-622.
105. McCarthy R., Arnold L., Babcock G. Dextran sulphate: an adjuvant for cell-mediated immune responses. Immunology 1977, 32:963.
106. Meerak J., Wanichwecharungruang S.P., Palaga T. Enhancement of immune response to a DNA vaccine against Mycobacterium tuberculosis Ag85B by incorporation of an autophagy inducing system. Vaccine 2013, 31(5):784-790. (Elsevier Ltd, Jan 21).
107. Mochizuki S., Sakurai K. Dectin-1 targeting delivery of TNF-α antisense ODNs complexed with β-1,3-glucan protects mice from LPS-induced hepatitis. J. Control. Release 2011, 151(2):155-161.
108. Mohit E., Hashemi A., Allahyari M. Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines. Expert. Rev. Clin. Immunol. 2014, 10(7):927-961. (Jul).
109. Mora-Solano C., Collier J.H. Engaging adaptive immunity with biomaterials. J. Mater. Chem. B 2014, 2(17):2409.
110. Nabel G.J. Designing tomorrow's vaccines. N. Engl. J. Med. 2013, 368(6):551-560.
111. Neimert-Andersson T., Binnmyr J., Enoksson M., Langebäck J., Zettergren L., Hällgren A.-C., et al. Evaluation of safety and efficacy as an adjuvant for the chitosan-based vaccine delivery vehicle ViscoGel in a single-blind randomised Phase I/IIa clinical trial. Vaccine 2014, 32(45):5967-5974. (Elsevier Ltd).
112. Ohtake S., Arakawa T. Recombinant therapeutic protein vaccines. Protein Pept. Lett. 2013, 20(12):1324-1344.
113. Oliveira C.R., Rezende C.M.F., Silva M.R., Borges O.M., Pêgo A.P., Goes A.M. Oral vaccination based on DNA-chitosan nanoparticles against Schistosoma mansoni infection. ScientificWorldJournal 2012, 2012:938457. (Jan).
114. Ott P.A., Fritsch E.F., Wu C.J., DranoffG. Vaccines and melanoma. Hematol. Oncol. Clin. N. Am. 2014, 28(3):559-569. (Elsevier Inc.; Jun).
115. Oyewumi M.O., Kumar A., Cui Z. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev. Vaccines 2010, 9(9):1095-1107.
116. Peine K.J., Bachelder E.M., Vangundy Z., Papenfuss T., Brackman D.J., Gallovic M.D., et al. Efficient delivery of the toll-like receptor agonists polyinosinic:polycytidylic acid and CpG to macrophages by acetalated dextran microparticles. Mol. Pharm. 2013, 10(8):2849-2857. (Aug 5).
117. Peluso G., Petillo O., Ranieri M., Santin M., Ambrosio L., Calabró D., et al. Chitosan-mediated stimulation of macrophage function. Biomaterials 1994, 15(15):1215-1220. (Dec).
118. Perrin-Cocon L., Agaugué S., Coutant F., Saint-Mézard P., Guironnet-Paquet A., Nicolas J.-F., et al. Lysophosphatidylcholine is a natural adjuvant that initiates cellular immune responses. Vaccine 2006, 24(9):1254-1263.
119. Petersen S.V., Thiel S., Jensenius J.C. The mannan-binding lectin pathway of complement activation: biology and disease association. Mol. Immunol. 2001, 38(2-3):133-149.
120. Petrovsky N., Cooper P.D. Carbohydrate-based immune adjuvants. Expert Rev. Vaccines 2011, 10(4):523-537.
121. Porporatto C., Bianco I.D., Correa S.G. Local and systemic activity of the polysaccharide chitosan at lymphoid tissues after oral administration. J. Leukoc. Biol. 2005, 78(1):62-69. (Jul).
122. Prego C., Torres D., Alonso M.J. Chitosan nanocapsules: a new carrier for nasal peptide delivery. J. Drug Deliv. Sci. Technol. 2006, 15(5):331-337.
123. Prego C., Paolicelli P., Díaz B., Vicente S., Sánchez A., González-Fernández Á., et al. Chitosan-based nanoparticles for improving immunization against hepatitis B infection. Vaccine 2010, 28(14):2607-2614.
124. Purcell A.W., McCluskey J., Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat. Rev. Drug Discov. 2007, 6(5):404-414.
125. Raemdonck K., Martens T.F., Braeckmans K., Demeester J., De Smedt S.C. Polysaccharide-based nucleic acid nanoformulations. Adv. Drug Deliv. Rev. 2013, 65(9):1123-1147.
126. Raghuwanshi D., Mishra V., Das D., Kaur K., Suresh M.R. Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein. Mol. Pharm. 2012, 9(4):946-956. (Apr 2).
127. Rappuoli R., Mandl C.W., Black S., De Gregorio E. Vaccines for the twenty-first century society. Nat. Rev. Immunol. 2011, 11(12):865-872. (Nature Publishing Group, Dec).
128. Reddy S.T., Rehor A., Schmoekel H.G., Hubbell J.A., Swartz M.A. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J. Control. Release 2006, 112(1):26-34.
129. Reddy S.T., Swartz M.A., Hubbell J.A. Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol. 2006, 27(12):573-579.
130. Reddy S.T., van der Vlies A.J., Simeoni E., Angeli V., Randolph G.J., O'Neil C.P., et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol. 2007, 25(10):1159-1164. (Oct).
131. Reed S.G., Bertholet S., Coler R.N., Friede M. New horizons in adjuvants for vaccine development. Trends Immunol. 2009, 30(1):23-32. (Jan).
132. Rice-Ficht A.C., Arenas-Gamboa A.M., Kahl-McDonagh M.M., Ficht T.A. Polymeric particles in vaccine delivery. Curr. Opin. Microbiol. 2010, 13(1):106-112.
133. Roman F., Vaman T., Gerlach B., Markendorf A., Gillard P., Devaster J.-M.M. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010, 28(7):1740-1745. (Feb 17).
134. Rosendahl Huber S., van Beek J., de Jonge J., Luytjes W., van Baarle D. T cell responses to viral infections - opportunities for peptide vaccination. Front. Immunol. 2014, 5(April):171. (Jan).
135. Ruan G.-X., Chen Y.-Z., Yao X.-L., Du A., Tang G.-P., Shen Y.-Q., et al. Macrophage mannose receptor-specific gene delivery vehicle for macrophage engineering. Acta Biomater. 2014, 10:1847-1855.
136. Sahdev P., Ochyl L.J., Moon J.J. Biomaterials for nanoparticle vaccine delivery systems. Pharm. Res. 2014, 31(10):2563-2582. (Oct).
137. Sánchez A., Villamayor B., Guo Y., McIver J., Alonso M.J. Formulation strategies for the stabilization of tetanus toxoid in poly(lactide-co-glycolide) microspheres. Int. J. Pharm. 1999, 185(2):255-266. (Aug 20).
138. Sawaengsak C., Mori Y., Yamanishi K., Mitrevej A., Sinchaipanid N. Chitosan nanoparticle encapsulated hemagglutinin-split influenza virus mucosal vaccine. AAPS PharmSciTech 2014, 15(2):317-325.
139. Sayin B., Somavarapu S., Li X., Thanou M., Sesardic D., Alpar H.O., et al. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery. Int. J. Pharm. 2008, 363:139-148.
140. Schalk J.A., Mooi F.R., Berbers G.A., van Aerts L.A., Ovelgönne H., Kimman T. Preclinical and clinical safety studies on DNA vaccines. Hum. Vaccin. 2006, 2(2):45-53.
141. Schully K.L., Sharma S., Peine K.J., Pesce J., Elberson M.A., Fonseca M.E., et al. Rapid vaccination using an acetalated dextran microparticulate subunit vaccine confers protection against triplicate challenge by Bacillus anthracis. Pharm. Res. 2013, 30(5):1349-1361. (May).
142. Schwendeman S., Costantino H., Gupta R.K., Tobío M., Chang A., Alonso M.J., et al. Strategies for stabilising tetanus toxoid towards the development of a single-dose tetanus vaccine. Dev. Biol. Stand. 1996, 87:293-306.
143. Sharma S., Mukkur T.K., Benson H.A., Chen Y. Enhanced immune response against pertussis toxoid by IgA-loaded chitosan-dextran sulfate nanoparticles. J. Pharm. Sci. 2012, 101(1):233-244.
144. Sharma S., Benson H.A., Mukkur T.K., Rigby P., Chen Y. Preliminary studies on the development of IgA-loaded chitosan-dextran sulphate nanoparticles as a potential nasal delivery system for protein antigens. J. Microencapsul. 2013, 30(3):283-294. (Informa Healthcare).
145. Shen L., Higuchi T., Tubbe I., Voltz N., Krummen M., Pektor S., et al. A trifunctional dextran-based nanovaccine targets and activates murine dendritic cells, and induces potent cellular and humoral immune responses in vivo. PLoS One 2013, 8(12):e80904.
146. Skwarczynski M., Toth I. Peptide-based subunit nanovaccines. Curr. Drug Deliv. 2011, 8(3):282-289.
147. Sletmoen M., Stokke B.T. Higher order structure of (1,3)-β-d-glucans and its influence on their biological activities and complexation abilities. Biopolymers 2008, 89(4):310-321. (Wiley Subscription Services, Inc., A Wiley Company; Apr).
148. Slütter B., Plapied L., Fiévez V., Alonso-Sande M., des Rieux A., Schneider Y.-J.J., et al. Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination. J. Control. Release 2009, 138(2):113-121. (Sep 1).
149. Slütter B., Bal S.M., Keijzer C., Mallants R., Hagenaars N., Que I., et al. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. Vaccine 2010, 28(38):6282-6291.
150. Slütter B., Bal S.M., Que I., Slütter B., Kaijzel E., Löwik C., et al. Antigen-adjuvant nanoconjugates for nasal vaccination: an improvement over the use of nanoparticles?. Mol. Pharm. 2010, 7(6):2207-2215.
151. Slütter B., Soema P.C., Ding Z., Verheul R., Hennink W.E., Jiskoot W. Conjugation of ovalbumin to trimethyl chitosan improves immunogenicity of the antigen. J. Control. Release 2010, 143(2):207-214. (Apr 19).
152. Sogias I.A., Williams A.C., Khutoryanskiy V.V. Why is chitosan mucoadhesive?. Biomacromolecules 2008, 9(7):1837-1842.
153. Soltanian S., Stuyven E., Cox E., Sorgeloos P., Bossier P. Beta-glucans as immunostimulant in vertebrates and invertebrates. Crit. Rev. Microbiol. 2009, 35(2):109-138.
154. Steinhagen F., Kinjo T., Bode C., Klinman D.M. TLR-based immune adjuvants. Vaccine 2011, 29(17):3341-3355.
155. Storni T., Kündig T.M., Senti G., Johansen P. Immunity in response to particulate antigen-delivery systems. Adv. Drug Deliv. Rev. 2005, 57(3):333-355. (Jan 10).
156. Sun H.-X., Xie Y., Ye Y.-P. ISCOMs and ISCOMATRIX. Vaccine 2009, 27(33):4388-4401. (Jul 16).
157. Tang C.K., Sheng K.-C.C., Pouniotis D., Esparon S., Son H.-Y.Y., Kim C.-W.W., et al. Oxidized and reduced mannan mediated MUC1 DNA immunization induce effective anti-tumor responses. Vaccine 2008, 26(31):3827-3834. (Jul 23).
158. Tang C.K., Sheng K.-C., Esparon S., Proudfoot O., Apostolopoulos V., Pietersz G.A. Molecular basis of improved immunogenicity in DNA vaccination mediated by a mannan based carrier. Biomaterials 2009, 30(7):1389-1400. (Elsevier Ltd; Mar).
159. The RTS.S Clinical Trials Partnership Efficacy and safety of the RTS, S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 2014, 11(7):e1001685. (Jul 29).
160. Thomann-Harwood L., Kaeuper P., Rossi N., Milona P., Herrmann B., McCullough K. Nanogel vaccines targeting dendritic cells: contributions of the surface decoration and vaccine cargo on cell targeting and activation. J. Control. Release 2013, 166(2):95-105.
161. Tincer G., Yerlikaya S., Yagci F.C., Kahraman T., Atanur O.M., Erbatur O., et al. Immunostimulatory activity of polysaccharide-poly(I:C) nanoparticles. Biomaterials 2011, 32:4275-4282.
162. Tobío M., Alonso M.J. Study of the inactivation process of the tetanus toxoid in contact with poly (lactic/glycolic acid) degrading microspheres. STP Pharma Sci. 1998, 8(5):303-310.
163. Tobío M., Gref R., Sánchez A., Langer R.S., Alonso M.J. Stealth PLA-PEG nanoparticles as protein carriers for nasal administration. Pharm. Res. 1998, 15(2):270-275. (Springer Netherlands; Feb).
164. Usonis V., Bakasénas V., Valentelis R., Katiliene G., Vidzeniene D., Herzog C. Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal®). Vaccine 2003, 21(31):45884592.
165. Vauthier C., Bouchemal K. Processing and scale-up of polymeric nanoparticles. Intracell Deliv Fundam Appl 2011, 433-456. Springer Science+Business Media. A. Prokop (Ed.).
166. Verheul R.J., Slütter B., Bal S.M., Bouwstra J.A., Jiskoot W., Hennink W.E. Covalently stabilized trimethyl chitosan-hyaluronic acid nanoparticles for nasal and intradermal vaccination. J. Control. Release 2011, 156(1):46-52.
167. Vicente S., Csaba N., Alonso M.J. From single-dose vaccine delivery systems to nanovaccines. J. Drug Deliv. Sci. Technol. 2010, 20(4):10.
168. Vicente S., Díaz-Freitas B., Peleteiro M., Sánchez A., Pascual D.W., González-Fernández Á., et al. A polymer/oil based nanovaccine as a single-dose immunization approach. PLoS One 2013, 8(4):e62500. (Public Library of Science).
169. Vicente S., Peleteiro M., Díaz-Freitas B., Sanchez A., González-Fernández Á., Alonso M.J. Co-delivery of viral proteins and a tlr7 agonist from polysaccharide nanocapsules: a needle-free vaccination strategy. J. Control. Release 2013, 172(3):773-781. (Elsevier B.V.; Dec 28).
170. Vicente S., Goins B.A., Sanchez A., Alonso M.J., Phillips W.T. Biodistribution and lymph node retention of polysaccharide-based immunostimulating nanocapsules. Vaccine 2014, 32(15):1685-1692. (Elsevier Ltd; Mar 26).
171. Vila A., Sánchez A., Janes K.A., Behrens I., Kissel T., Vila-Jato J.L., et al. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur. J. Pharm. Biopharm. 2004, 57(1):123-131. (Jan).
172. Vila A., Sánchez A., Evora C., Soriano I., McCallion O., Alonso M.J. PLA-PEG particles as nasal protein carriers: the influence of the particle size. Int. J. Pharm. 2005, 292(1-2):43-52. (Mar 23).
173. Wang J., Guo C., Yue T., Yuan Y., Liu X., Kennedy J.F. Cationization of Ganoderma lucidum polysaccharides in concentrated alkaline solutions as gene carriers. Carbohydr. Polym. 2012, 88(3):966-972.
174. Wilson-Welder J.H., Torres M.P., Kipper M.J., Mallapragada S.K., Wannemuehler M.J., Narasimhan B. Vaccine adjuvants: current challenges and future approaches. J. Pharm. Sci. 2009, 98(4):1278-1316.
175. www.clinicaltrials.gov Trial identifier: NCT00005023. Last visited in August 2014 2014, U. S. National Institutes of Health.
176. www.fda.gov Last Visited in August 2014 2014, U.S. Food and Drug Administration.
177. Xiang S.D., Selomulya C., Ho J., Apostolopoulos V., Plebanski M. Delivery of DNA vaccines: an overview on the use of biodegradable polymeric and magnetic nanoparticles. WIREs Nanomed. Nanobiotechnol. 2010, 2(3):205-218.
178. ZaharoffD.A., Rogers C.J., Hance K.W., Schlom J., Greiner J.W. Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine 2007, 25(11):2085-2094. (Mar 1).
179. Zolnik B.S., González-Fernández Á., Sadrieh N., Dobrovolskaia M.A. Nanoparticles and the immune system. Endocrinology 2010, 151(2):458-465. (Feb).